ValiRx PLC

EAJF

Company Profile

  • Business description

    ValiRx PLC is a UK-based biopharmaceutical and life sciences company focused on advancing cutting-edge therapies in healthcare. The Company mainly engages in developing technologies and products in oncology therapeutics and diagnostics, with a focus on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It develops therapeutics across fields in oncology and has a portfolio of products in the pipeline, including GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in different stages of development.

  • Contact

    D6 Thane Road
    MediCity Nottingham
    NottinghamNG90 6BH
    GBR

    T: +44 1157840026

    E: [email protected]

    https://www.valirx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    11

Stocks News & Analysis

stocks

AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event

We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
stocks

The most popular ASX trades in FY26

A closer look at the stocks and ETFs that captured Aussie investors’ attention in FY26.
stocks

Chart of the Week: The CBA chart you can’t ignore

Where value remains in Australian banks.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,018.1041.40-0.46%
CAC 408,299.09138.80-1.64%
DAX 4024,763.12392.29-1.56%
Dow JONES (US)51,711.65506.93-0.97%
FTSE 10010,639.1777.80-0.73%
HKSE25,210.81318.151.28%
NASDAQ25,137.69553.21-2.15%
Nikkei 22566,422.60307.000.46%
NZX 50 Index13,795.310.000.00%
S&P 5007,408.3090.66-1.21%
S&P/ASX 2008,839.0038.60-0.43%
SSE Composite Index3,876.789.740.25%

Market Movers